Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics Inc (CTNM) is a clinical-stage biopharmaceutical company pioneering oral small molecule therapies for complex conditions including idiopathic pulmonary fibrosis (IPF) and relapsing-remitting multiple sclerosis. This news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access verified information about CTNM's innovative pipeline, including the LPA1 receptor inhibitor PIPE-791 for pulmonary fibrosis and muscarinic receptor modulator PIPE-307 for neurological conditions. Our curated news collection covers essential updates without speculative commentary, ensuring reliable tracking of the company's progress in addressing unmet medical needs.
Key content includes trial phase results, research collaborations, and scientific presentations. Bookmark this page for streamlined monitoring of Contineum's advancements in small molecule drug development and its position within the competitive biopharmaceutical landscape.
Contineum Therapeutics (NASDAQ: CTNM) has provided an update on its Phase 1b PET trial of PIPE-791, a selective LPA1 receptor antagonist. The company has completed enrollment for healthy volunteer and progressive multiple sclerosis (PrMS) cohorts, with 12 healthy volunteers and 4 PrMS patients enrolled to date.
The trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy using PET imaging. Due to the addition of two PrMS patients in early June, the company now expects to report topline data in Q3 2025, representing a modest delay. Enrollment for idiopathic pulmonary fibrosis (IPF) patients is still ongoing.
ArrePath (NASDAQ:CTNM) has announced the successful completion of a new financing round led by Boehringer Ingelheim Venture Fund, with participation from existing investors Insight Partners, Innospark, Nor'easter Ventures, and new investor AB Magnitude. The funding, combined with non-dilutive awards from PACE and CARB-X, will support the advancement of their lead program AP-001 and expand their antimicrobial compound development.
Additionally, the company has appointed Dr. Diego Miralles as the new Chair of the Board of Directors. Dr. Miralles brings extensive biotech and pharmaceutical industry experience, having served as CEO of multiple companies including AZURNA Therapeutics, Laronde, and Vividion Therapeutics, and held senior positions at Johnson & Johnson.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, May 20th at 8:30 a.m. ET. Investors and interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
Contineum Therapeutics (NASDAQ: CTNM) has appointed Timothy Watkins, M.D., M.Sc. as its new Chief Medical Officer and Head of Development. Dr. Watkins, formerly Vice President at Gilead Sciences, brings extensive experience in immunology and fibrotic disease therapeutic development.
Key highlights:
- Dr. Watkins succeeds Stephen L. Huhn, who served as CMO since 2020
- Company plans to initiate Phase 2 clinical trial for idiopathic pulmonary fibrosis in second half of 2025
- Dr. Watkins received inducement awards including: - Time-based stock option for 260,000 shares - Performance-based stock option for 26,000 shares
The appointment aligns with Contineum's enhanced focus on inflammation, immunology, and fibrotic disease development. The company's pipeline includes PIPE-307 for multiple sclerosis and depression, developed in partnership with Johnson & Johnson.
Contineum Therapeutics (NASDAQ: CTNM) has appointed Diego Miralles, M.D. to its Board of Directors, effective March 14, 2025. Dr. Miralles, currently CEO of AZURNA Therapeutics, brings extensive experience in novel therapy development and clinical trials.
Dr. Miralles' career includes leadership roles at Laronde Inc. (2020-2022), Vividion Therapeutics (2017-2020), and Johnson & Johnson (2007-2016). He currently serves on the board of Artiva Biotherapeutics and chairs its Clinical Strategy Committee. His academic background includes an M.D. from the University of Buenos Aires, residency at Mayo Clinic, and fellowship at The New York Hospital/Cornell University.
Contineum, a clinical-stage biopharmaceutical company, focuses on developing therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company is preparing to initiate multiple proof-of-concept clinical trials.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the Stifel 2025 Virtual CNS Forum.
The company's management will deliver a presentation on Tuesday, March 18th at 12:30 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
Contineum Therapeutics (NASDAQ: CTNM) has reported its Q4 2024 financial results and clinical development milestones. The company ended Q4 2024 with $204.8 million in cash and equivalents, projecting runway through 2027.
Key upcoming milestones include:
- PIPE-791 Phase 1b PET trial topline data expected in Q2 2025
- PIPE-307 Phase 2 VISTA trial data for RRMS treatment anticipated in H2 2025
- Phase 2 proof-of-concept trials for IPF and PrMS planned for H2 2025
- PIPE-791 Phase 1b chronic pain trial topline data expected in early 2026
Financial highlights show R&D expenses at $13.0 million (62% increase YoY), G&A expenses at $4.0 million, and a net loss of $14.6 million for Q4 2024.
Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in a Phase 1b trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting chronic pain treatment. The randomized, double-blind, placebo-controlled, crossover trial will evaluate the drug's safety, tolerability, and pain reduction effectiveness.
The study focuses on chronic pain associated with osteoarthritis (OA) and low back pain (LBP). The trial will enroll approximately 40 patients across five U.S. sites, with a 28-day treatment duration. Topline data is expected in early 2026.
PIPE-791 works by blocking the lysophosphatidic acid 1 receptor (LPA1R), potentially modifying maladaptive changes in the central nervous system associated with chronic pain. The drug aims to provide a non-opioid treatment alternative for patients suffering from OA and LBP.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the 2025 Leerink Partners Global Healthcare Conference.
The company's management will deliver a presentation on Tuesday, March 11th at 3:00 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
FAQ
What is the current stock price of Contineum Therapeutics (CTNM)?
What is the market cap of Contineum Therapeutics (CTNM)?
